Details for Patent: 8,772,497
✉ Email this page to a colleague
Which drugs does patent 8,772,497 protect, and when does it expire?
Patent 8,772,497 protects FYCOMPA and is included in two NDAs.
This patent has fifty-three patent family members in twenty-eight countries.
Summary for Patent: 8,772,497
| Title: | Method for producing 1, 2-dihydropyridine-2-one compound |
| Abstract: | The present inventions provide a method for commercially producing a 1,2-dihydropyridine-2-one compound represented by the following formula (III-a) ##STR00001## wherein the ring A represents an optionally substituted 2-pyridyl group, the ring B represents an optionally substituted phenyl group, and the ring C represents an optionally substituted phenyl group. Further, the invention provides crystals of 3-(2-cyanophenyl)-5-(2-pyridyl)-1-phenyl-1,2-dihydropyridin-2-one and production processes therefore. |
| Inventor(s): | Arimoto; Itaru (Tokyo, JP), Nagato; Satoshi (Tokyo, JP), Sugaya; Yukiko (Tsukuba, JP), Urawa; Yoshio (Kamisu, JP), Ito; Koichi (Tsukuba, JP), Naka; Hiroyuki (Kamisu, JP), Omae; Takao (Tsukuba, JP), Kayano; Akio (Kamisu, JP), Nishiura; Katsutoshi (Kamisu, JP) |
| Assignee: | Eisai R&D Management Co., Ltd. (Tokyo, JP) |
| Application Number: | 12/870,507 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,772,497 |
|
Patent Claim Types: see list of patent claims | Compound; Process; |
Drugs Protected by US Patent 8,772,497
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Catalyst Pharms | FYCOMPA | perampanel | SUSPENSION;ORAL | 208277-001 | Apr 29, 2016 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Catalyst Pharms | FYCOMPA | perampanel | TABLET;ORAL | 202834-001 | Oct 22, 2012 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Catalyst Pharms | FYCOMPA | perampanel | TABLET;ORAL | 202834-002 | Oct 22, 2012 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| Catalyst Pharms | FYCOMPA | perampanel | TABLET;ORAL | 202834-003 | Oct 22, 2012 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,772,497
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| Japan | 2004-198709 | Jul 6, 2004 |
International Family Members for US Patent 8,772,497
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Austria | E547405 | ⤷ Try a Trial | |||
| Australia | 2005258378 | ⤷ Try a Trial | |||
| Australia | 2005258385 | ⤷ Try a Trial | |||
| Brazil | PI0510254 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
